New hepatitis B drug from GSK wipes out all signs of the virus in some patients

A new experimental drug for chronic hepatitis B has demonstrated the potential to provide a “functional cure,” allowing some patients to cease treatment while keeping the virus under control. Researchers reported these findings on Thursday, marking a significant development in the decades-long search for alternatives to lifelong therapy.

Did You Know? Chronic hepatitis B affects more than 250 million people worldwide and is responsible for approximately 1.1 million deaths annually due to complications like liver failure and liver cancer.

A Breakthrough in Viral Control

The drug, known as bepirovirsen or “bepi,” was developed by GSK and Ionis Pharmaceuticals. It functions by binding to the genetic components of the hepatitis B virus, suppressing viral replication and a key surface protein known as the “S” protein, while simultaneously stimulating the immune system.

Expert Insight

In two international studies involving 1,838 patients, those who received the experimental drug alongside their regular medication saw a marked improvement. Approximately 1 in 5 recipients achieved a functional cure, meaning their virus remained undetectable for six months after stopping all treatment. No patients in the control group, who received a dummy shot, achieved this result.

Expert Insight: The significance of this development lies in the nature of hepatitis B, which has historically been difficult to treat because it hides within the body. By moving beyond simple viral suppression to a state where the immune system can manage the virus independently, this therapy could potentially change the standard of care for millions, provided that long-term remission can be consistently maintained.

What Lies Ahead

The path forward for bepirovirsen depends on ongoing regulatory reviews and further clinical observation. The U.S. Food and Drug Administration is currently conducting a fast-track review of the drug, with a decision expected in October. Regulators in Europe, China and Japan are also considering the treatment.

A New Hope for Hepatitis B Patients | Bepirovirsen Sodium | Hepatitis B New Treatment | GSK

Future studies may clarify why some patients respond better to the treatment than others, particularly those who begin the process with lower levels of the “S” protein. While initial data from earlier-stage trials showed that most patients remained well up to three years later, experts emphasize that more research is needed to determine the duration of this remission-like state and to assess outcomes for patients with more complex conditions, such as cirrhosis.

Frequently Asked Questions

What is a “functional cure” for hepatitis B?
A functional cure occurs when a patient’s virus is reduced to levels low enough for the immune system to keep it in check, allowing them to stop treatment without the virus rebounding.

How does the new drug, bepirovirsen, work?
The drug binds to the virus’s genetic components to suppress replication and a key surface protein, while also stimulating the patient’s immune system.

Were there any side effects reported?
Researchers noted side effects included mild pain or redness at the injection site and a temporary increase in enzymes, which can be a sign of liver stress.

How might the availability of a functional cure change the way we approach long-term management of chronic viral infections?